BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm

<p>The database is related to the article &ldquo;BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm&rdquo;. In this database we reported all the clinical and anamnestic data of the patients who completed the trial (e.g. 32 high-frequency episodic migraine subjects and 28 of them completed the trial).&nbsp; After a 28-day baseline period, subjects underwent 4 subsequent onabotulinum toxin-A treatments according to the phase III research evaluating migraine prophylaxis therapy (PREEMPT) paradigm, 12-weeks apart. Onabotulinum toxin-A reduced monthly migraine days by 3.68 days. Thirty-nine percent of the patients experienced a &ge;50% reduction in monthly migraine days. Onabotulinum toxin-A also reduced the number of headache days and the intake of acute medications. Disability and quality of life (QoL) scores improved markedly.</p>